(Total Views: 780)
Posted On: 06/06/2022 9:26:44 PM
Post# of 148899
Quote:
Dr. Hope Rugo is the Director of the Breast Oncology Clinical Trials Program at UCSF. She is the principal investigator for multiple clinical trials studying novel targeted therapeutics combined with standard treatments to improve clinical results in early and late-stage breast cancer. She is also researching cognitive function in patients receiving chemotherapy for breast cancer as well as ways to reduce toxicity from therapy .
from here: https://www.theoncologypharmacist.com/confere...ast-cancer
Quote:
Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy .
and given the work being done at MD Anderson, what do you think the possibility is of CytoDyn announcing a partnership in a trial of LL in combination with Keytruda PD-1 Inhibitor Pembrolizumab for mTNBC?
No chemo. Well tolerated, minimal side effects. same or better OS and PFS.
(6)
(0)Scroll down for more posts ▼
